Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | PLEC | Q15149 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.48 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492746 | 0.92 | POLB (0.54) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL3491664 | 0.90 | RNASEH1 (0.58) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL3492123 | 0.90 | MAPT (0.57) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL14650893 | 0.89 | MAPT (0.58) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL3492896 | 0.89 | RNASEH1 (0.57) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL3492155 | 0.89 | KMT2A (0.60) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL4505873 | 0.88 | KMT2A (0.64) | POLBL3MBTL1MAPTALDH1A1KMT2A | |
| Meglumine SCHEMBL21459106 | 0.87 | POLB (0.45) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL3494842 | 0.87 | MAPT (0.58) | POLBTDP1L3MBTL1PLECMAPT | |
| SCHEMBL3494852 | 0.87 | KMT2A (0.61) | POLBTDP1L3MBTL1PLECMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481399-A1 | METHODS FOR TREATMENT OF HEART FAILURE | Cardurion Pharmaceuticals, LLC (US) | 2019-05-15 | — | — | EP | claimed |
| WO-2018009899-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS, LLC (US) | 2018-01-11 | — | — | WO | claimed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | claimed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | claimed |
| US-10870656-B2 | Methods for treatment of heart failure | CARDURION PHARMACEUTICALS, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-10870656-B2 | Methods for treatment of heart failure | CARDURION PHARMACEUTICALS, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2019204298-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3481399-A1 | METHODS FOR TREATMENT OF HEART FAILURE | Cardurion Pharmaceuticals, LLC (US) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018009899-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS, LLC (US) | 2018-01-11 | — | — | WO | disclosed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | POLB 555/4885TDP1 409/4885L3MBTL1 3167/4885 |
| US-10870656-B2 | Methods for treatment of heart failure | TNNT2, TNNI3, TNNC1 | POLB 1353/4885TDP1 1594/4885L3MBTL1 671/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | POLB 2134/4885TDP1 76/4885L3MBTL1 602/4885 |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | TNNT2, TNNI3, TNNC1 | POLB 1353/4885TDP1 1594/4885L3MBTL1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.